Nxstage Medical (NASDAQ: NXTM) Hits New All-Time High at $27.12

[okarol]

Nxstage Medical (NASDAQ: NXTM) Hits New All-Time High at $27.12
January 19th, 2011 • View Comments • Filed Under • by ABMN Staff

Shares of Nxstage Medical (NASDAQ: NXTM) hit a new all-time high on Wednesday. The stock traded as high as $27.12 during mid-day trading and last traded at $26.14. The stock previously closed at $26.80.

On a related note, analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Nxstage Medical in a research note to investors on Monday, January 3rd. Separately, analysts at Lazard Capital initiated coverage on shares of Nxstage Medical in a research note to investors on Friday, December 17th. They set a “buy” rating and a $30.00 price target on the stock.

NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its product, the NxStage System One (System One), was designed to satisfy an unmet clinical need for a system that can deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable form that can be used by healthcare professionals and trained lay users alike in a range of settings, including patient homes, as well as more traditional care settings, such as hospitals and dialysis clinics. NxStage markets the System One to dialysis clinics for chronic hemodialysis treatment, providing clinics with access to a developing market, the home hemodialysis market and the ability to expand their patient base by adding home-based patients without adding clinic infrastructure.

Nxstage Medical (NASDAQ: NXTM) traded down 3.40% during mid-day trading on Wednesday. The stock has a 52 week low of $7.60 and a 52 week high of $26.81. Its 50-day moving average is $24.14 and its 200-day moving average is $19.61. The company has a market cap of $1.274 billion and a price-to-earnings ratio of N/A.

http://www.americanbankingnews.com/2011/01/19/nxstage-medical-nasdaq-nxtm-hits-new-all-time-high-at-27-12/

[greg10]

Nxstage Medical (NASDAQ: NXTM) Hits New All-Time High at $27.12
January 19th, 2011 • View Comments • Filed Under • by ABMN Staff

Shares of Nxstage Medical (NASDAQ: NXTM) hit a new all-time high on Wednesday. The stock traded as high as $27.12 during mid-day trading and last traded at $26.14. The stock previously closed at $26.80...

No consolation for those of us who didn't receive our allotted cartridges and supplies this month.  "It seemed like they missed the delivery this month.  We apologize for the delay, the delivery will be next Tuesday".

True story.

The did promised to UPS next day those items we are out of.

[DrMoskowitz]

If anybody here is holding dialysis-related stock (e.g. Fresenius, DaVita, Amgen, NxStage, etc.), I'd consider dumping it. Once my paper (1) is public knowledge, dialysis stocks may take a dive, as they well deserve to (http://tinyurl.com/healthcrime).

Reference
1:  Moskowitz DW. From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. Diabetes Technol Ther. 2002;4(4):519-32.
PMID: 12396747. (http://www.genomed.com/pdf/diabetes.technology.therapeutics.pdf).

[greg10]

If anybody here is holding dialysis-related stock (e.g. Fresenius, DaVita, Amgen, NxStage, etc.), I'd consider dumping it. Once my paper is public knowledge ..

I don't know doc, your paper was published in 2002.  When do you think your GenoMed stock is going to start trading again?

St. Louis Business Journal
Date: Friday, March 5, 2010, 6:40pm CST
"Shares of GenoMed have been suspended from trading by the Securities and Exchange Commission, which said Wednesday the company has been delinquent in filing required reports with the regulatory agency.

The St. Louis-based medical genomics company hasn’t filed a periodic report with the SEC since the first quarter of 2005.

GenoMed trades on the Pink Sheets (Pink Sheets: GMED). It last traded Monday at one-half cent per share."
http://www.bizjournals.com/stlouis/stories/2010/03/01/daily83.html

.. and did you really said this?
"It's going to be the fountain of youth," Moskowitz said. "There are a lot of physicians who say ACE inhibitors are so good, they should be in the drinking water. And I'm basically of that school."

[DrMoskowitz]

You have correctly observed that my company's stock is no longer trading, as we lacked the revenue to keep paying $100K to lawyers and auditors for quarterly SEC filings. The filings are a bit of a racket. A few hours' work cost $25K! In 2005, I decided it wasn't worth it. However, when we have money to burn, we'll go back to reporting to the SEC again.

My point is that my 2002 paper got no press at the time, and none since. The media refused to say a word about my paper without endorsement from somebody in the renal community. And not a single person in the renal community has come forward to endorse my paper. Either my paper is total garbage, or the renal community doesn't want ESRD eliminated. Why don't you read my paper and decide?

Meanwhile, all the dialysis stocks are trading for lots of money. If you think this is a stable situation, you must not believe in truth or science at all.

[greg10]

..
My point is that my 2002 paper got no press at the time, and none since. The media refused to say a word about my paper ..

http://www.daily-diabetic.com/50226711/aceinhibitor_diabetes_prevention_drug_fails_in_trial.php
August 30, 2006
Though researchers had high hopes for the role of the ACE-inhibitor drug ramipril (brand name Altace) in preventing Type 2 diabetes, they had to declare the experiment a bust.

"Given the primary findings of the DREAM trial, ramipril cannot be recommended for the prevention of type 2 diabetes," wrote Julie R. Ingelfinger, M.D., and Caren G. Solomon, M.D., M.P.H., both deputy editors of NEJM, in an accompanying editorial.

[DrMoskowitz]

Altace isn't the ACE inhibitor we use. Most of them don't work. We found one that did back in 1994, and a second one in 2001-2006. A third works; we just found out with an FSGS patient last summer. What they share is a high affinity for the N-terminal active site of ACE.